Embed Size (px)
Citation preview
Marta Gómez Quintanilla Spanish Representative – Health & IMI - H2020
CDTI – MICIUN marta.gomez[at]cdti.es
Sevilla, 25th Sept. 2018
* Acudan a las webs oficiales para disponer de la información más actualizada
Horizon 2020:
Opportunities for biotechnology Now & in the Future
Oportunities
Looking at the future
Final recommendations
Oportunities
Looking at the future
Final recommendations
The EU Framework Programme for Research and Innovation
Essential part of European Strategy: Europe 2020
Focus on societal challenges e.g. Health, Bioeconomy…
75.028 M€
Partnerships: Public-Private, Public-Public
International cooperation (beyond EU)
2014-2020
The EU Framework Programme for Research and Innovation
Open to the
world
1- Excellent science
€24.3 billion
2- Industrial leadership
€16.6 billion
3- Societal challenges
€28.6 billion
Society driven: • Address concerns
of citizens and society/EU policy
objectives • Multidisciplinary
collaborations
Industry driven: • Strategic
investments in key technologies • Support to innovative companies
Researchers driven: Excellent science is the
foundation of tomorrow’s
technologies, jobs and wellbeing
3 priorities: Opportunities in all for biotech
Priorities & budget (€)
Medical Techs: nano, biomaterials…
Biotech: all colours
Grey
Green, blue
Red
Industrial Partnerships
(JTIs)
1.638 M€
1.638 M€
Access: Participant Portal Work Programme: 2018 some calls still open, 2019 OPEN, 2020 in definition,
only titles
https://ec.europa.eu/research/participants/portal/desktop/en/home.html
Some examples:
Mainly:
- Grants
- to European Consortia (+ 3 partners/+ 3 member states)
- up to 100% of the budget + 25% overheads (up to 70% to industrial partners when innovation actions)
Differente deadlines & types of action (see additional slides)
Still 2+ years of calls!
Many opportunities on the table!
8
Focus in Industrial Leadership & Societal Challenges
Support
LINK to Spanish NCPs: http://eshorizonte2020.es/que-es-horizonte-2020/horizonte-2020-en-espana/puntos-nacionales-de-contacto
WP definition
Strategic orientation, Future initiatives
Proposal Preparation
Projects follow-up 915815562
Oportunities
Looking at the future
Final recommendations
Commission proposal (texts under discussion in the European Parliament and Council) -> not final version!!!
11
HORIZON EUROPE
Framework Programme for Research and Innovation
2021-2027
94.100 M€
European Strategy & Beyond: Boosting the Union's competitiveness and growth Helping to achieve Sustainable Development Goals
Pillars & Budget: BIOTECH in all 3 pillars Medical Technologies: nano, biomaterials…
Grey
Green, blue
Red
Commission proposal (texts under discussion in the European Parliament
and Council) -> not final version!!!
Oportunities
Looking at the future
Final recommendations
Multi-disciplinar
Multi-sectorial
Multi-stakeholder
Other aspects tbc: gender, etc.
Team work: build a network
Be ready
Be active
Get support
Final recommendations
CONTACT:
Marta Gómez Quintanilla
Spanish Representative - HEALTH
Spanish Representative - IMI
Spanish MB Member - JPND
34 91 581 55 62 / 00
marta.gomez[at]cdti.es - www.cdti.es
http://bit.ly/1nj1ToZ
@EsHorizonte2020
@EU_RDI_LifeSci
* Acudan a las webs oficiales para disponer de la información más actualizada
Annex
Details & Deadlines
Societal Challenge 1: Health Demographic Change and wellbeing
Objectives:
Improve health and well-being outcomes,
promote healthy and active ageing,
promote market growth, job creation, and the EU as a global leader in the health area.
Better health for all
7 Priorities
3 calls + other actions
Call 'Better Health and care, economic growth and sustainable health systems'
apro
x.
2.0
00
M€
Call 'Digital transformation in Health and Care'
Call 'Trusted digital solutions and Cybersecurity in Health and Care'
Other Actions 2018–2019
Single-stage: 16/April/19
Two-Stage: 1st stage: 02/Oct/18
2nd stage: 16/April/19
24/April/19
14/Nov/19
Special characteristics
Deadlines 2019
Objective
To speed up the development of better and safer medicines for
patients. IMI supports collaborative research
projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
www.imi.europa.eu
IMI2 FORMULA
Call 15
Topic 1: Integrated research platforms enabling patient-centric drug development
Topic 2: Blockchain Enabled Healthcare
Topic 3: Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
Topic 4: Emerging translational safety technologies and tools for interrogating human immuno-biology
Topic 5: Development and validation of translational platforms in support of synaptopathy drug discovery
Topic 6: Digital endpoints in neurodegenerative and immune-mediated diseases
Topics under the IMI2 Antimicrobial Resistance (AMR) Accelerator programme
Topic 7: AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
Topic 8: AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
23
Open Calls Reference CE Opening Deadline Budget
H2020-JTI-IMI2-2017-15 18/07/18 24/10/18 (2nd stage 15/05/19) 386,7 M€
H2020-JTI-IMI2-2017-16 18/07/18 24/10/18 46,9 M€
www.imi.europa.eu/apply-funding/open-calls
Call 16
Topic 1: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Topic 2: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
Topic 3: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
Topic 4: Determination of gepotidacin levels in tonsils and prostatic tissue
Topic 5: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
Topic 6: Functional Ethionamide boosters: a novel combination for tuberculosis therapy
Topic 7: Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)
Support
LINK to Spanish NCPs: http://eshorizonte2020.es/que-es-horizonte-2020/horizonte-2020-en-espana/puntos-nacionales-de-contacto
Marta Gómez Quintanilla (Representante)
marta.gomez[at]cdti.es
Carolina Carrasco (NCP- Punto Nacional de Contacto) carolina.carrasco[at]cdti.es
Marta de Diego (Experta IMI) marta.dediego[at]cdti.es
915815562
CDTI support in
Health
Carolina Carrasco (CDTI) - [email protected]
Juan Riese (ISCIII) - [email protected] NCPs Health
25
Societal
Challenges
Industrial
Technologies
Excellent
Science
BUDGET
Societal Challenge 2: Food Security, Sustainable Agricultura and Forestry, Marine, Maritime and Inland Water Research and the Bioeconomy
26
Call Blue
Growth
Call Sustainable Food
Security
Call Rural Reinassance
LC
Low Carbon
DT
Digitisation
CE
Circular Economy
WP 2018-2020.- 3 Calls & 3 Virtual Focus areas
WP update – 24th July 2018
27
Societal Challenge 2 - WP 2018-2020 – Publication 24 July 2018. Calls 2019
Budget of 2019 calls: Sustainable Food Security: 293,1 mio€ Blue Growth: 89,0 mio€ Rural Renaisance: 84,5 mio€ Opening of the call: 16 October 2018 Closing dates: Single stage and First stage – 23 January 2019 Second stage – 4 September 2019 Work Program 2018-2020 - SC2 – Updated version 24 July 2018 http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-food_en.pdf Próximo evento informativo: Infoday y taller en CDTI el 10 de octubre de 2018. Inscripción y agenda en el enlace.
466,6 mio €
28
Representante en el Comité de Programa
José Manuel González
Puntos Nacionales de Contacto (NCP)
Marta Conde (CDTI)
Jesús Escudero (INIA)
Contactos en España
Horizon 2020 – Reto Social 2 Bioeconomía
29
Societal
Challenges
Industrial
Technologies
Excellent
Science
BUDGET
H2020 – Framework Programme for Research & Innovation
30
Cutting-edge biotechnologies as future innovation drivers
Biotechnology-based industrial processes driving competitiveness and sustainability
Innovative and competitive platform technologies
Horizon 2020 – NMBP – BIOTECHNOLOGY – Specific Program
Work Program 2018-2020 - NMBP – Updated version 24 July 2018 http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-leit-nmp_en.pdf
31
H2020- Biotechnology – Call 2019. Opening of the call: 16 October 2018 BIOTEC-02-2019: Boosting the efficiency of photosynthesis (RIA)
• TRL 3-5 • EU contribution between 6 and 8 mio€. Available budget. 31mio€ • Evaluation procedure: 2 stages. • Closing dates: First stage: 22/01/2019. Second stage: 3/09/2019
CE-BIOTEC-05-2019 Microorganism communities for plastics bio-degradation (RIA)
• EU-China flagship initiative. Chinese participants will apply under Chinese co-funding mechanishm. • TRL: 3-5 • EU contribution 5mio€. Available budget 10mio€. • Evaluation procedure: Single Stage. • Closing dates: 24/04/2019
BIOTEC-06-2020: Reprogrammed microorganisms for biological sensors (IA) BIOTEC-07-2020: Multi-omics for the optimisation of genotype-phenotype associations(RIA)
H2020- Biotechnology – Call 2020
WP 2018-2020 – Publication 24 July 2018 41 mio €
32
Representante en el Comité de Programa
Lucía Iñigo (CDTI)
lucia.iñ[email protected]
Puntos Nacionales de Contacto (NCP)
Marta Conde (CDTI) - BIOTECNOLOGIA
Jesús Escudero (INIA) - BIOTECNOLOGIA
Nieves González – NMP
Carlos León (UCM) - NMP
Contactos en España
Horizon 2020 – NMBP - BIOTECHNOLOGY
BBI JU aims to develop sustainable and competitive bio-based industries in Europe, based on advanced biorefineries that source their biomass sustainably.
• 4 strategic orientations: feedstock, process, products & market-uptake
CALL 2019 (Single stage call)
• Type of actions: RIA, IA-DEMO, IA-FLAGSHIP, CSA
• Indicative budget: 135 M€
• Pre-publication AWP 2019: end december 2018
• Publication date: April 2019
• Deadline: September 2019
33
Bio-based Industries JU (BBI JU)
www.bbi-europe.eu
H2020: Web, & twitter
www.eshorizonte2020.es
@EsHorizonte2020
www.guiah2020.es
AAL: Active and Assisted Living www.aal-europe.eu
COCIR: European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry www.cocir.org
EC: European Commission http://ec.europa.eu
EDCTP: The European and Developing Countries Clinical Trials Partnership www.edctp.org
EJP: European Joint Programme http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/other/index.html
EFPIA: The European Federation of Pharmaceutical Industries and Associations www.efpia.eu
EIP: European Innovation Partnership https://ec.europa.eu/research/innovation-union/index.cfm?pg=eip
EIT: European Institute of Innovation & Technology http://eit.europa.eu
EMPIR: European Metrology Programme for Innovation and Research www.emrponline.eu
FET: Future and Emerging Technologies http://ec.europa.eu/programmes/horizon2020/en/h2020-section/future-and-emerging-technologies
HBP: Human Brain Project www.humanbrainproject.eu
IMI: Innovative Medicines Initiative www.imi.europa.eu
JPI AMR: Joint Programming in Antimicrobial Resistance www.jpiamr.eu
JPI HD&HL: A Healthy diet for a healthy life www.healthydietforhealthylife.eu
JPI MYBL: Joint Programming More Years, Better Lives www.jp-demographic.eu
JPI: Joint Programming Initiative http://ec.europa.eu/research/era/joint-programming_en.htm
JPND: Joint Programming in Neurodegenerative Research www.neurodegenerationresearch.eu
KIC: Knowledge and Innovation Community http://eit.europa.eu/kics
PPP: Public-Private Partnership & P2P: Public-Public Partnership http://ec.europa.eu/research/era/partnership/partnering_en.htm
SME: Small and medium-sized enterprises http://ec.europa.eu/enterprise/policies/sme/index_en.htm
GLOSSARY & LINKS
